Vimarsana
Biggest News Aggregation in the World

Page 2 - Sight Biologic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sight Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sight Biologic Today - Breaking & Trending Today

GenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 million - Vimarsana News

GenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 million

Published: November 15, 2023

15.11.2023 - Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system ...

Source: wallstreet-online.de
Related Topics:
France GeneralGensight BiologicsEuropean Medicines AgencySofinnova PartnersSight BiologicsBridge FinancingSight BiologicMitochondrial Targeting SequenceLeber Hereditary Optic NeuropathyGensight BiologicInstitut De La VisionAdeno Associated VirusMedicines AgencyProcess Performance QualificationGood Manufacturing PracticeMarketing Authorisation ApplicationBiologics License ApplicationGensight Biologics Stock
GenSight Biologics: Annual General Meeting on June 21, 2023 - Vimarsana News

GenSight Biologics: Annual General Meeting on June 21, 2023

Published: May 31, 2023

Procedures for obtaining preparatory documents for the General Meeting Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on

Source: finanznachrichten.de
Related Topics:
France GeneralGensight BiologicsGuillaume Van RenterghemClothilde CailletGensight Biologics EuronextCorporate CommunicationsSight BiologicsAnnual General MeetingFaubourg Saint AntoineGeneral MeetingFrench Commercial CodeCommercial CodeSight BiologicMitochondrial Targeting SequenceLeber Hereditary Optic NeuropathyGensight BiologicCommunications Director
GenSight Biologics S A : Notice of General Meeting to be held on the 21th of June, 2023 - Vimarsana News

GenSight Biologics S A : Notice of General Meeting to be held on the 21th of June, 2023

Published: May 31, 2023

CONVENING OF THE COMBINED GENERAL MEETING ON MAY 25, 2022 GENSIGHT BIOLOGICS A French Société Anonyme ... | May 31, 2023

Source: marketscreener.com
Related Topics:
United KingdomUnited StatesFrance GeneralSaint AntoineGensight BiologicsCompanies RegistryNational Agency For MedicinesRegulatory AgencyFrench Competent AuthorityFda Us Food Drug AdministrationHealth Products Safety Agence Nationale DeFrench SociFaubourg Saint AntoineSight BiologicMitochondrial Targeting SequenceGensight BiologicLeber Hereditary Optic NeuropathyTemporary AuthorisationFrench National Drug Safety AgencyAgence NationaleGood Manufacturing PracticesMarketing Authorisation ApplicationCombined General MeetingNature MedicineSpecial Protocol Assessment
GenSight Biologics S A : Convening notice – 2023 General Meeting - Vimarsana News

GenSight Biologics S A : Convening notice – 2023 General Meeting

Published: May 31, 2023

CONVENING OF THE COMBINED GENERAL MEETING ON JUNE 21, 2023 GENSIGHT BIOLOGICS A French Société Anonyme ... | May 31, 2023

Source: marketscreener.com
Related Topics:
United KingdomUnited StatesSaint AntoineFrance GeneralGensight BiologicsCompanies RegistryEuropean Medicines AgencyFrench SociFaubourg Saint AntoineSight BiologicMitochondrial Targeting SequenceLeber Hereditary Optic NeuropathyGensight BiologicMarket Authorisation ApplicationTemporary AuthorizationsEarly Access AuthorisationCombined General MeetingGood Manufacturing PracticesMarketing Authorisation ApplicationHeights CapitalLeber Hereditary Optical NeuropathyTheir RelativesGensight Biologics Sa Stock ExchangePress ReleaseNonyme Sight Fr0013183985
GenSight Biologics Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023 - Vimarsana News

GenSight Biologics Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023

Published: May 10, 2023

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for

Source: finanznachrichten.de
Related Topics:
France GeneralJames PalmerBernard GillyGensight Biologics EuronextThomas GidoinClothilde CailletGuillaume Van RenterghemJeanene TimberlakeGensight BiologicsCorporate CommunicationsRegulatory NewsSight BiologicsRegistration DocumentDes MarchScientific AdviceChief Executive OfficerChief Financial OfficerAnnual General MeetingSight BiologicMitochondrial Targeting SequenceLeber Hereditary Optic NeuropathyGensight BiologicCommunications DirectorGefallene Big Techs